Sail Medical: Shareholders with more than 5% equity reduce their holdings by 3.0912 million shares, accounting for 1.47%.

Saili Medical announced that before the implementation of the reduction plan, Shanghai Angze held 12.1 million shares of the company, accounting for 5.76% of the total share capital. On October 1, 2025, Shanghai Angze disclosed the reduction plan, intending to reduce no more than 4.2028 million shares from October 30, 2025 to January 29, 2026, accounting for 2% of the total share capital. As of January 28, 2026, Shanghai Angze has completed the reduction, reducing a total of 3.0912 million shares through centralized bidding and block trades, accounting for 1.47% of the total share capital as of January 20, 2026, with a total reduction amount of 65.2263 million yuan. After the reduction, Shanghai Angze holds 9.0092 million shares, accounting for 4.29%.